HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $12 Price Target
Benzinga Newsdesk 10 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $12 price target.
HC Wainwright & Co. analyst Brandon Folkes reiterates Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and maintains $12 price target.